37 research outputs found

    Autoimmune aspects of diabetes mellitus.

    Get PDF

    Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells.

    Get PDF
    A novel eicosanoid, 5,6-trans-epoxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-trans-EET), was identified in rat red blood cells. Characterization of 5,6-trans-EET in the sn-2 position of the phospholipids was accomplished by hydrolysis with phospholipase A(2) followed by gas chromatography/mass spectrometry as well as electrospray ionization-tandem mass spectrometry analyses. The electron ionization spectrum of 5,6-erythro-dihydroxyeicosatrienoic acid (5,6-erythro-DHET), converted from 5,6-trans-EET in the samples, matches that of the authentic standard. Hydrogenation of the extracted 5,6-erythro-DHET with platinum(IV) oxide/hydrogen resulted in an increase of the molecular mass by 6 daltons and the same retention time shift as an authentic standard in gas chromatography, suggesting the existence of three olefins as well as the 5,6-erythro-dihydroxyl structure in the metabolite. Match of retention times by chromatography indicated identity of the stereochemistry of the red blood cell 5,6-erythro-DHET vis à vis the synthetic standard. High pressure liquid chromatography-electrospray ionization-tandem mass spectrometry analysis of the phospholipase A(2)-hydrolyzed lipid extracts from red blood cells revealed match of the mass spectrum and retention time of the compound with the authentic 5,6-trans-EET standard, providing direct evidence of the existence of 5,6-trans-EET in red blood cells. The presence of other trans-EETs was also demonstrated. The ability of both 5,6-trans-EET and its product 5,6-erythro-DHET to relax preconstricted renal interlobar arteries was significantly greater than that of 5,6-cis-EET. In contrast, 5,6-cis-EET and 5,6-trans-EET were equipotent in their capacity to inhibit collagen-induced rat platelet aggregation, whereas 5,6-erythro-DHET was without effect. We propose that the red blood cells serve as a reservoir for epoxides which on release may act in a vasoregulatory capacity

    Title Page Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal COX-2 expression and enhanced renal prostaglandin release. JPET #129197 2 Running Title Page Running title: Fenofibrate and renal COX-2 in diabetes. Abbreviations AA -arac

    No full text
    Abstract Renal COX-2 expression is increased in the diabetic rat and has been linked to increased GFR and renal injury. Our studies indicate that oxidative stress in the form of peroxynitrite (ONOO) may be the stimulus for induction of COX-2. In this study, we addressed the effects of a PPARα agonist on renal COX-2 expression as fibrates exert renal protective effects. 48h after the induction of diabetes with streptozotocin in male Wistar rats, fenofibrate treatment (100mg/kg/day) was started and the effects compared to untreated diabetic rats and treated and untreated age-matched control rats (n=5 per group). After 12-14 weeks of treatment, the right kidney was perfused to determine prostaglandin release in response to arachidonic acid (AA) and the left kidney used to examine the expression of COX-2 and nitrotyrosine, an index of ONOO formation. Release of PGE 2 in response to AA was enhanced in the diabetic rat kidney compared to control (4.8±0.7 vs 1.9±0.7ng/min) and reduced by fenofibrate to 0.6±0.2ng/min. A similar pattern was obtained for AA-stimulated release of 6-ketoPGF 1α . The effects of fenofibrate were associated with reduced renal expression of COX-2 and nitrotyrosine in diabetic rats. We used creatinine clearance as an index of GFR, which was increased in the diabetic rat, 3.09±0.4 vs 1.15±0.1ml/min for control, and reduced by fenofibrate treatment to 1.87±0.3ml/min. These results show that fenofibrate treatment of diabetic rats decreases renal COX-2 expression, possibly by reducing nitrosative stress, and is associated with a reduction of the enhanced GFR
    corecore